Protocol Ledger

NCT04189445 · Phase II · TERMINATED

Futibatinib in Patients With Specific FGFR Aberrations

Interventional Phase II clinical trial protocol NCT04189445 sponsored by Taiho Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-05 Enrollment: 115 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04189445
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)115 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04189445
Protocol FieldVerified Registry Value
NCT IdentifierNCT04189445
Consolidated Lead SponsorTaiho Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment115 participants (ACTUAL)
Registered Start Date2020-08-05
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI